SafeGuardRx® changes coming soon

In 2024, HIVCV contributed less than 1% of the overall value that plans received from SafeGuardRx. This program will be retired, and we will continue to support at-risk members through other patient-centric nonadherence solutions within our organization.

In recent years, utilization has shifted from brand-name medications to more affordable generics and average manufacturer price caps have also reduced the cost of several drugs included within the program. As these market changes have organically solved most of what PCV was designed to address, this program will also be retired.

After a careful review of outcomes and performance, we’ve decided to sunset this program. We remain committed to improving patient adherence and do so through the following specialty programs: Inflammatory and Atopic Conditions Care Value^SM, Multiple Sclerosis Care Value Program^SM, Oncology Care Value Program® and Rare Conditions Care Value® Program.

The 120-day threshold for discontinuation credit will be removed to remain consistent with other programs within the platform. Plans will receive discontinuation credits per month per 30-day prescription for a total of 90 days if a member falls off therapy. Early discontinuation rates will be revised as part of an ongoing commitment to platform organization.